Name: Pearce IP
Address: Level 5/20 Bond St, Sydney, NSW, 2000, AU
Telephone: (02) 9023 9988
Price range: $$

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

A Double Blow for Moderna - Seqirus Topples Two mRNA Patent Applications

By Helen Macpherson, Naomi Pearce | Feb 09, 2026

Read more

Seqirus Inc. v ModernaTX, Inc. [2025] APO 15 (23 May 2025) / Seqirus Inc. v ModernaTX, Inc. [2025] APO 21

Date of decision:
23 May 2025/ 4 July 202...
UPDATE – Patentee/Sponsor Industry Organisations Buy-in on Otsuka PTE Loss

By Naomi Pearce, Helen Macpherson | Feb 06, 2026

Read more

IPTA and MA seek to intervene in Otsuka’s Application for Leave to appeal to Australia’s High Court

On 30 January 2026, two industry organisations – ...
Court of Appeal Rules That "Consumers Are Not Stupid" - Lego v Zuru

By Paul Johns, Kimberley Evans | Feb 06, 2026

Read more

Zuru v Lego [2025] NZCA 650 (10 December 2025)

Date of decision:
10 December 2025

Body:
New Zealand Court of Appeal

Adjudicator:
mAbxience/HK inno.N’s Biosimilar Denosumab Approved in Korea

By Bioblast Editor | Feb 05, 2026

Read more

On 5 February 2026, Korea Biomedical Review reported that Korean headquartered HK inno.N has received approval from Korea’s Ministry of Food and Drug Safety for Izambia Prefilled Syringe and Denbrayce Injection, biosimilars to Amgen’s Prolia® and Xgeva® respectively.
CVS Offers Samsung Bioepis’ & Celltrion’s Denosumab Biosimilars, Drops Amgen’s Prolia® from Formularies

By Bioblast Editor | Feb 05, 2026

Read more

On 5 February 2026, CVS Health announced that pharmacy benefits manager, CVS Caremark, will begin offering Samsung Bioepis’ Ospomyv® and Celltrion’s Stoboclo®, biosimilars to Amgen’s Prolia® (denosumab), on major US national commercial template formularies from 1 April 2026...
Alvotech Announces Positive Results from Ph 1 Biosimilar Vedolizumab Study

By Bioblast Editor | Feb 05, 2026

Read more

On 5 February 2026, Alvotech announced positive results from a pharmacokinetic study for AVT80, biosimilar to Takeda’s Entyvio® (vedolizumab).

The Phase 1 study evaluated the comparative pharmacokinetics, safety, immunogenicity and tolerability between AVT80 and Enty...
Hanging By a Thread - Samsung Invalidates Janssen’s UC Ustekinumab (Stelara®) Patent Application

By Helen Macpherson, Paul Johns | Feb 05, 2026

Read more

Samsung Bioepis AU Pty Ltd v Janssen Biotech, Inc. [2025] APO 32 (3 October 2025)

Date of decision:
3 October 2025

Body:
Australian Paten...
When “Routine Chemistry” Isn’t Routine - Key Lessons from a Recent APO Decision

By Sally Paterson, Helen Macpherson | Feb 04, 2026

Read more

Adama Agan Ltd. v Kumiai Chemical Industry Co., Ltd. [2025] APO 41

Date of decision:
28 November 2025

Body:
Australian Patent Office
...
Saya Biologics & Kashiv BioSciences Ink Deal for Oncology Biosimilar

By Bioblast Editor | Feb 04, 2026

Read more

On 4 February 2026, Mexican-headquartered Saya Biologics announced that it has entered a strategic collaboration agreement with Kashiv BioSciences for commercialisation of an undisclosed supportive biosimilar oncology therapy in Mexico and the Central America and Caribbean ...
R-Pharm’s Biosimilar Cetuximab Approved in Russia

By Bioblast Editor | Feb 04, 2026

Read more

On 4 February 2026, R-Pharm announced it has obtained Russian marketing authorisation for the anti-cancer drug Arcetux™, biosimilar to Eli Lilly/Merck KgGa’s Erbitux® (cetuximab). This is the first biosimilar cetuximab to be approved in Russia.

Arcetux™ has been app...